Table 6.

List of vaccines authorized for combating the SARS CoV-2 and their reported efficacies.

S. No	Vaccine Name	Type of Vaccine	Primary Developers	Vaccine Efficacy on SARS-CoV-2 Wild Type or Variants	Primary End Point or Outcome	Number of Doses of Vaccination
1	BNT162b2 (Comirnaty)	mRNA-based vaccine	Pfizer, BioNTech; Fosun Pharma	SARS-CoV-2: 95% [76] Omicron: 70% [22]	Safety over a median of 2 months was similar to that of other viral vaccines	Two doses
2	mRNA-1273 (Spikevax)	mRNA-based vaccine	Moderna, BARDA, NIAID	SARS-CoV-2: 94.1% [130] Omicron: 85% [132]	The primary end point was prevention of COVID-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2.	Two doses
3	AstraZeneca (AZD1222 also known as Vaxzevria and Covishield	Adenovirus vaccine	BARDA, OWS	74% (Overall) and an efficacy of 83.5% in participants age 65 years and older [140]	Preventing the onset of symptomatic and severe coronavirus disease 2019 (COVID-19) 15 days or more after the second dose in adults, including older adults	Two doses
4	Sputnik V (Gam-COVID-Vac)	Recombinant adenovirus vaccine (rAd26 and rAd5)	Gamaleya Research Institute, Acellena Contract Drug Research and Development	91.6% [143]	The primary outcome was the proportion of participants with PCR-confirmed COVID-19 from day 21 after receiving the first dose.	Two doses
5	Janssen (JNJ-78436735; Ad26.COV2.S)	Non-replicating viral vector	Janssen Vaccines (Johnson & Johnson)	52.9% against moderate or severe-to-critical COVID-19 and 41.7% against any infection [150]	The primary end points were vaccine efficacy against moderate to severe–critical COVID-19 with onset at least 14 days after administration	Single dose
6	CoronaVac	Inactivated vaccine (formalin with alum adjuvant)	Sinovac	65.9% for the prevention of COVID-19 and 87.5% for the prevention of hospitalization, 90.3% for the prevention of ICU admission, and 86.3% for the prevention of COVID-19–related death [161]	Estimated the change in the hazard ratio associated with partial immunization (≥14 days after receipt of the first dose and before receipt of the second dose) and full immunization (≥14 days after receipt of the second dose)	Both Single and Double dose
7	BBIBP-CorV (Vero Cells) also called as Covilo	Inactivated vaccine	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	78.1% [155]	Primary outcome was efficacy against laboratory-confirmed symptomatic COVID-19 14 days following a second vaccine dose among participants who had no virologic evidence of SARS-CoV-2 infection at randomization. The secondary outcome was efficacy against severe COVID-19.	Two Doses
8	Convidicea (PakVac, Ad5-nCoV)	Recombinant vaccine (adenovirus type 5 vector)	CanSino Biologics	57.5% [148]	The primary efficacy objective evaluated Ad5-nCoV in preventing symptomatic, PCR-confirmed COVID-19 infection occurring at least 28 days after vaccination in all participants who were at least 28 days postvaccination	Single dose
9	Covaxin (BBV152)	Inactivated vaccine	Bharat Biotech, ICMR; Ocugen; ViroVax	77.8% [165]	The primary outcome was the efficacy of the BBV152 vaccine in preventing a first occurrence of laboratory-confirmed (RT-PCR-positive) symptomatic COVID-19 (any severity), occurring at least 14 days after the second dose in the per-protocol population.	Two Doses
10	WIBP-CorV	Inactivated vaccine	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	72.8% [155]	Primary outcome was efficacy against laboratory-confirmed symptomatic COVID-19 14 days following a second vaccine dose among participants who had no virologic evidence of SARS-CoV-2 infection at randomization. The secondary outcome was efficacy against severe COVID-19.	Two Doses
11	Zycov-D	DNA vaccine (plasmid)	Zydus Cadila	66.6% [186]	The primary outcome was the number of participants with first occurrence of symptomatic RT-PCR-positive COVID-19 28 days after the third dose	Three doses
12	Nuvaxovid (Covovax in India; previously NVX-CoV2373)	Recombinant nanoparticle vaccine	Novavax CEPI, Serum Institute of India	89.7% [190]	The primary efficacy end point was virologically confirmed mild, moderate, or severe SARS-CoV-2 infection with an onset at least 7 days after the second injection in participants who were serologically negative at baseline.	Two doses
13	Covifenz (CoVLP)	Plant-based adjuvant vaccine	Medicago; GSK; Dynavax	78.8% [195]	The primary objective of the trial was to determine the efficacy of the CoVLP+AS03 vaccine in preventing symptomatic coronavirus disease 2019 (COVID-19) beginning at least 7 days after the second injection	Two Doses
14	Soberana 02/Soberana Plus	Conjugate vaccine	Finlay Institute of Vaccines; Pasteur Institute	92.4% [182]	Study endpoints are vaccine efficacy (VE) evaluated through confirmed symptomatic COVID-19 and safety	Three doses